A random walk approach to estimate the confinement of α-particle emitters in nanoparticles for targeted radionuclide therapy
Authors:
Open Access
- 30 May 2018
- journal article
- review article
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 3 (1) , 1-26
Abstract
Targeted radionuclide therapy is a highly efficient but still underused treatment modality for various types of cancers that uses so far mainly readily available β-emitting radionuclides. By using α-particle emitters several shortcomings due to hypoxia, cell proliferation and in the selected treatment of small volumes such as micrometastasis could be overcome. To enable efficient targeting longer-lived α-particle emitters are required. These are the starting point of decay chains emitting several α-particles delivering extremely high radiation doses into small treatment volumes. However, as a consequence of the α-decay the daughter nuclides receive high recoil energies that cannot be managed by chemical radiolabelling techniques. By safe encapsulation of all α-emitters in the decay chain in properly sized nanocarriers their release may be avoided. The encapsulation of small core nanoparticles loaded with the radionuclide in a shell structure that safely confines the recoiling daughter nuclides promises good tumour targeting, penetration and uptake, provided these nanostructures can be kept small enough. A model for spherical nanoparticles is proposed that allows an estimate of the fraction of recoiling α-particle emitters that may escape from the nanoparticles as a function of their size. The model treats the recoil ranges of the daughter nuclides as approximately equidistant steps with arbitrary orientation in a three-dimensional random walk model. The presented model allows an estimate of the fraction of α-particles that are emitted from outside the nanoparticle when its size is reduced below the radius that guarantees complete confinement of all radioactive daughter nuclides. Smaller nanoparticle size with reduced retention of daughter radionuclides might be tolerated when the effects can be compensated by fast internalisation of the nanoparticles by the target cells.Keywords
Funding Information
- European Commission
This publication has 65 references indexed in Scilit:
- Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug moleculesAdvanced Drug Delivery Reviews, 2013
- Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid LeukemiaClinical Cancer Research, 2010
- Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I StudyJournal of Nuclear Medicine, 2009
- Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to ClinicCritical Reviews™ in Therapeutic Drug Carrier Systems, 2009
- Therapeutic Radionuclides: Biophysical and Radiobiologic PrinciplesSeminars in Nuclear Medicine, 2008
- Enhanced Loading Efficiency and Retention of225Ac in Rigid Liposomes for Potential Targeted Therapy of MicrometastasesBioconjugate Chemistry, 2008
- Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6Journal of Nuclear Medicine, 2007
- Enhanced Retention of the α-Particle-Emitting Daughters of Actinium-225 by Liposome CarriersBioconjugate Chemistry, 2007
- Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclidesNuclear Medicine and Biology, 2004
- Paths and Chains of Random Straight-Line SegmentsTechnometrics, 1966